See more : Capital Metals plc (CMET.L) Income Statement Analysis – Financial Results
Complete financial analysis of Pasithea Therapeutics Corp. (KTTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pasithea Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- GE Vernova Inc. (GEV) Income Statement Analysis – Financial Results
- Permanent TSB Group Holdings plc (IL0A.L) Income Statement Analysis – Financial Results
- Pegatron Corporation (4938.TW) Income Statement Analysis – Financial Results
- Bangkok Chain Hospital Public Company Limited (BCH-R.BK) Income Statement Analysis – Financial Results
- Epsilon Healthcare Limited (EPN.AX) Income Statement Analysis – Financial Results
Pasithea Therapeutics Corp. (KTTA)
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 486.56K | 15.06K | 0.00 |
| Cost of Revenue | 648.45K | 113.20K | 17.28K | 0.00 |
| Gross Profit | -648.45K | 373.36K | -2.21K | 0.00 |
| Gross Profit Ratio | 0.00% | 76.74% | -14.69% | 0.00% |
| Research & Development | 8.10M | 2.67M | 0.00 | 0.00 |
| General & Administrative | 7.88B | 9.92M | 0.00 | 0.00 |
| Selling & Marketing | -7.87B | 2.60M | 0.00 | 0.00 |
| SG&A | 7.88M | 12.52M | 4.51M | 40.98K |
| Other Expenses | 0.00 | 44.72K | 0.00 | 0.00 |
| Operating Expenses | 15.98M | 15.19M | 4.51M | 40.98K |
| Cost & Expenses | 15.98M | 15.30M | 4.52M | 40.98K |
| Interest Income | 0.00 | 102.00 | 508.00 | 0.00 |
| Interest Expense | 0.00 | 102.00 | 508.00 | 0.00 |
| Depreciation & Amortization | 648.45K | 5.09K | 1.38K | 61.48K |
| EBITDA | -15.33M | -12.58M | -4.51M | 0.00 |
| EBITDA Ratio | 0.00% | -3,029.28% | -29,916.57% | 0.00% |
| Operating Income | -15.98M | -14.82M | -4.51M | -40.98K |
| Operating Income Ratio | 0.00% | -3,045.12% | -29,925.73% | 0.00% |
| Total Other Income/Expenses | 471.61K | 861.09K | 2.33M | -4.00 |
| Income Before Tax | -15.51M | -13.94M | -2.17M | -40.98K |
| Income Before Tax Ratio | 0.00% | -2,864.29% | -14,430.49% | 0.00% |
| Income Tax Expense | 0.00 | -879.97K | 508.00 | -61.48K |
| Net Income | -15.96M | -13.06M | -2.17M | -40.98K |
| Net Income Ratio | 0.00% | -2,683.43% | -14,433.87% | 0.00% |
| EPS | -12.65 | -10.34 | -1.89 | -0.06 |
| EPS Diluted | -13.01 | -10.34 | -1.89 | -0.06 |
| Weighted Avg Shares Out | 1.26M | 1.26M | 1.15M | 688.92K |
| Weighted Avg Shares Out (Dil) | 1.23M | 1.26M | 1.15M | 688.92K |
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern Europe in the coming months -- --...
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO, Calif. and MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:...
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout expected as...
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that it held its annual meeting of stockholders (the “Annual Meeting”) on December 19, 2023.
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%.
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?
Pasithea Therapeutics (NASDAQ: KTTA ) stock is rocketing higher on Monday after the biotechnology company announced results from two preclinical trials of PAS-004. The first study saw positive results from PAS-004 as a treatment for lung cancer.
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24.
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that its annual meeting of stockholders held on November 29, 2023 (the “Annual Meeting”) was convened and...
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
-- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004 Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF and NF1 mutations -- SOUTH SAN FRANCISCO, Calif. and MIAMI,...
Source: https://incomestatements.info
Category: Stock Reports